Verve Therapeutics Inc (VERV) Reports Progress and Financials for Q4 and Full Year 2023 [Yahoo! Finance]
Verve Therapeutics, Inc. (VERV)
Company Research
Source: Yahoo! Finance
Collaboration Revenue : Increased to $5.1 million for Q4 2023, and $11.8 million for the full year. R&D Expenses : Rose to $46.8 million for Q4 2023, totaling $184.9 million for the year. G&A Expenses : Grew to $12.3 million for Q4 2023, with an annual total of $49.9 million. Net Loss : Reported at $48.4 million for Q4 2023, and $200.1 million for the full year. Warning! GuruFocus has detected 1 Warning Sign with VERV. On February 27, 2024, Verve Therapeutics Inc ( NASDAQ:VERV ) released its 8-K filing , detailing its financial results for the fourth quarter and the full year of 2023. The company, a trailblazer in genetic medicines for cardiovascular disease, is advancing its pipeline with three clinical-stage programs targeting PCSK9 and ANGPTL3 genes, expected to enter clinical trials in 2024. Verve Therapeutics Inc ( NASDAQ:VERV ) operates as a single segment within the United States, focusing on developing single-course gene editing medicines for cardiovascular diseas
Show less
Read more
Impact Snapshot
Event Time:
VERV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VERV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VERV alerts
High impacting Verve Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VERV
News
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
- Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
- Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
- Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
VERV
Earnings
- 11/7/23 - Beat
VERV
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- VERV's page on the SEC website